Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRP-032
- Development stage
- Preclinical
- Lead developer
- Venus Remedies
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
VRP-032 is a biomimetic antimicrobial infusion therapy under development by Venus Remedies for the treatment of septicaemia and infections caused by extremely drug-resistant (XDR) pathogens, including WHO priority and ESKAPE pathogens. It has demonstrated preclinical efficacy against resistant bacteria, viruses, fungi, and other faulty proteins. The drug is currently in the preclinical stage of development, with formulation and development (F&D) completed.
Beyond the preview
Go deeper on VRP-032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRP-032.